List of Excipients in Branded Drug MERREM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	MERREM	meropenem	0069-0314	SODIUM CARBONATE

MERREM Excipient Strategy and Commercial Opportunities for Meropenem Injection

Last updated: August 9, 2026

Merrem is the former branded intravenous formulation of meropenem, a carbapenem antibiotic. Its core excipient platform is simple: sterile meropenem powder with sodium carbonate as the formulation excipient. The commercial opportunity is therefore not based on recreating a complex branded formulation. It is based on improving reconstitution, stability, administration convenience, container systems, pharmacy workflow, and supply reliability while preserving meropenem’s established intravenous performance.

In the United States, the primary commercial barrier is generic competition rather than a live Merrem formulation patent estate. Meropenem injection is approved through abbreviated new drug applications, and the original product’s regulatory exclusivity has expired. The strongest opportunities are differentiated presentations that reduce preparation time, minimize medication errors, improve cold-chain flexibility, or address hospital procurement needs.

What is the Merrem formulation and which excipients does it contain?

Merrem IV is a sterile powder for intravenous administration containing meropenem and sodium carbonate. The product is supplied in single-dose vials, commonly in 500 mg and 1 g strengths. Sodium carbonate is used to control formulation pH and support meropenem stability in the dry state and after reconstitution. The product does not rely on a large excipient system, preservative package, surfactant, or complex delivery technology. [1]

Product attribute	Merrem IV position
Active ingredient	Meropenem
Drug class	Carbapenem antibacterial
Route	Intravenous
Dosage form	Sterile powder for solution
Common strengths	500 mg and 1 g
Principal excipient	Sodium carbonate
Preservatives	Not used in the standard single-dose vial
Primary administration settings	Hospitals, intensive care, emergency departments
FDA approval	NDA 050706; approved in the 1990s
Current market structure	Generic-dominated

Meropenem is chemically sensitive to aqueous conditions, temperature, concentration, diluent, and storage duration. The dry powder format avoids many of the stability constraints associated with ready-to-use liquid carbapenems. Any alternative excipient strategy must therefore be evaluated against the risk of accelerated degradation after reconstitution.

Why is sodium carbonate used in Merrem?

Sodium carbonate provides alkalinity and buffering capacity. Meropenem stability is linked to the pH of the reconstituted solution, and the formulation must remain within a range suitable for chemical stability and intravenous administration. The excipient also contributes to the product’s sodium load, which matters for patients receiving high doses or prolonged therapy.

A reformulation that removes or materially changes sodium carbonate would require evidence that the alternative buffer maintains:

• Meropenem potency and impurity profile.
• Acceptable solution pH.
• Compatibility with approved diluents.
• Suitable osmolality and infusion tolerability.
• Stability during preparation, storage, and administration.
• Compatibility with infusion bags, tubing, filters, and elastomeric devices.

The principal formulation risk is that a new buffer may improve one attribute, such as room-temperature stability, while creating another problem, such as higher degradation products or greater vascular irritation.

What patents protect Merrem and meropenem injection?

The original Merrem composition and manufacturing patent estate is not a material barrier to ordinary generic meropenem injection in the United States. Meropenem was approved decades ago, and the basic compound and conventional injectable formulation are no longer protected by active U.S. exclusivity.

A commercial assessment should distinguish four different IP categories:

IP category	Relevance to Merrem and meropenem
Meropenem compound patents	Historically important; generally expired in major markets
Basic sterile powder formulation	Generally open to generic competition
Method-of-use patents	May have covered specific clinical uses historically; not a broad barrier to injectable meropenem
Delivery and container patents	Can remain relevant for premixes, dual-chamber systems, infusion devices, or proprietary packaging

The absence of a blocking compound patent does not mean every product design is free of patent risk. A manufacturer pursuing a ready-to-use bag, dual-chamber vial, elastomeric pump, or specialized reconstitution device must conduct a separate freedom-to-operate review covering container systems, oxygen control, terminal sterilization, aseptic filling, and device claims.

Is Merrem listed in the Orange Book?

Merrem IV was approved under NDA 050706. The current Orange Book position should be checked against FDA’s live listing because marketed status and patent-listing status can change after product discontinuation or sponsor updates. The relevant commercial point is that generic meropenem injection has long been available and is not dependent on a pending Paragraph IV challenge to an active Merrem exclusivity right. [2]

When did Merrem lose exclusivity?

Merrem lost practical market exclusivity after expiration of the original regulatory and patent protections for meropenem. FDA approval occurred in the 1990s, and the five-year new chemical entity exclusivity period would have ended approximately five years after approval. Generic meropenem products subsequently entered the U.S. market.

Exclusivity element	Commercial effect
New chemical entity exclusivity	Expired
Original compound protection	Expired in major jurisdictions
Basic injectable formulation protection	No longer a meaningful generic barrier
Pediatric exclusivity	Not a current barrier
Current competition	Multiple generic suppliers and hospital-contract manufacturers

Because the relevant protections are expired, the principal launch issue is ANDA approval, product quality, manufacturing capacity, and purchasing contracts rather than Paragraph IV litigation.

Which companies are challenging Merrem exclusivity?

Meropenem is already a mature generic market. The competitive field includes established generic injectable manufacturers and contract manufacturers that supply hospital distributors, group purchasing organizations, and government channels. The commercial challenge is not typically a branded-generic patent dispute. It is obtaining approval, demonstrating reliable supply, and winning formulary or contract share.

Potential competitors include suppliers of:

• Meropenem for injection in 500 mg and 1 g vials.
• Generic products packaged for pharmacy admixture.
• Ready-to-use meropenem infusion bags.
• Extended-infusion hospital products.
• Contract-manufactured products for institutional buyers.

The relevant competitive dataset is FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. It identifies approved abbreviated applications and therapeutic-equivalence information. [2]

What excipient strategies can differentiate meropenem products?

The strongest strategy is to keep the excipient system conservative while changing the presentation. Meropenem is a mature injectable antibiotic, so physicians and hospital pharmacists are unlikely to accept unnecessary formulation complexity unless it creates a measurable operational benefit.

1. Optimized carbonate-buffered powder

A manufacturer can retain sodium carbonate but optimize:

• Buffer quantity.
• Cake or powder density.
• Reconstitution time.
• Residual moisture.
• Vial headspace.
• Nitrogen or controlled-atmosphere filling.
• Stopper and seal compatibility.

This approach has the lowest regulatory and clinical risk. The product remains close to the reference presentation while improving manufacturing robustness and pharmacy handling.

2. Reduced-sodium formulation

A lower-sodium formulation could appeal to hospitals treating patients with renal impairment, heart failure, or high cumulative intravenous fluid and electrolyte exposure. The opportunity is limited because the sodium contribution from the excipient is only one part of total treatment exposure, and changing the buffer may create stability or pH risks.

A reduced-sodium product would require comparative data showing that the revised formulation maintains chemical stability, acceptable osmolality, and equivalent clinical performance. The commercial claim should focus on sodium exposure and preparation characteristics, not on superior antibacterial efficacy.

3. Ready-to-use liquid bags

Ready-to-use meropenem could reduce pharmacy compounding, staff time, contamination risk, and dose-preparation errors. The principal technical challenge is aqueous stability. A liquid product may require:

• Concentration-specific stability work.
• Low-temperature storage.
• Light and oxygen control.
• Specialized multilayer bags.
• Overwrap protection.
• Validated in-use stability.
• Defined excursion limits.

The opportunity is strongest in intensive care units, emergency departments, outpatient parenteral antimicrobial therapy, and hospitals with centralized pharmacy compounding. The disadvantage is higher manufacturing complexity and greater inventory risk than a dry powder vial.

4. Dual-chamber vials and bags

A dual-chamber container separates dry meropenem from the diluent until administration. This design can preserve powder stability while eliminating manual reconstitution. It may deliver much of the operational value of a ready-to-use liquid without requiring long-term aqueous stability.

The commercial barriers are device development, container-closure validation, human-factors testing, fill-finish investment, and potential device-related patent claims. The product may be more suitable for hospital and outpatient settings than for price-sensitive commodity procurement.

5. Elastomeric and ambulatory infusion systems

Meropenem is used in prolonged or extended infusions in some hospital protocols because time-dependent antibacterial exposure is clinically relevant. A prefilled elastomeric device could support outpatient therapy and reduce daily pharmacy manipulation.

The formulation must be compatible with the device over the full labeled storage and administration period. Testing must address sorption, leachables, extractables, flow rate, temperature, and potency. This is a higher-value opportunity than a conventional vial, but it requires coordinated drug-device development.

What formulations are protected by Merrem-related patents?

The conventional Merrem powder formulation is not the central IP opportunity. New protection may be available for narrowly defined formulation and delivery features if they meet novelty, nonobviousness, enablement, and written-description requirements.

Potentially protectable subject matter includes:

• Specific meropenem-to-buffer ratios.
• Low-moisture sterile powder compositions.
• Defined impurity limits after reconstitution.
• Stabilized aqueous meropenem solutions.
• Particular pH and concentration ranges.
• Dual-chamber container configurations.
• Oxygen-scavenging or barrier packaging.
• Extended-infusion products with defined in-use stability.
• Elastomeric pump formulations.
• Lyophilized or spray-dried presentations.
• Manufacturing processes that reduce degradation products.

Patent value depends on claim breadth and design-around difficulty. A patent limited to one concentration, one bag material, or one narrow stability condition may have little blocking power if competitors can use another concentration or container.

What is the FDA regulatory pathway for a new meropenem excipient strategy?

A conventional generic meropenem powder for injection generally proceeds through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence as applicable, along with quality, sterility, stability, and manufacturing compliance.

A materially different presentation may require a different pathway.

Product concept	Likely regulatory route
Same active, strength, route, and basic powder presentation	ANDA
New excipient or materially different formulation	ANDA assessment or 505(b)(2), depending on FDA determination
Ready-to-use bag with new device characteristics	505(b)(2) or drug-device combination review
Dual-chamber delivery system	Combination-product assessment
New clinical use	505(b)(2), potentially with method-of-use exclusivity
New pediatric or outpatient indication	Depends on the scope of the proposed labeling and supporting data

FDA may permit certain inactive-ingredient differences in an ANDA if they do not affect safety, efficacy, quality, or performance. A novel excipient, materially different concentration, or new delivery technology raises a greater risk of 505(b)(2) review.

What generic launch risks exist for Merrem?

Pricing and contracting risk

Meropenem injection is a hospital generic. Buyers commonly evaluate price, shortage history, reliability, packaging, and wholesaler availability. A differentiated formulation must generate enough labor savings or supply value to offset a price premium.

Manufacturing risk

Sterile injectable manufacturing is the main barrier to entry. Relevant risks include:

• Aseptic processing failures.
• Particulate contamination.
• Sterility failures.
• Inadequate vial or bag supply.
• Meropenem degradation during filling.
• Inconsistent reconstitution performance.
• Inspection findings at contract manufacturing sites.

Supply-chain risk

Carbapenems are strategically important hospital antibiotics. Procurement organizations may value dual sourcing, domestic production, and shortage resilience. A manufacturer with a reliable sterile facility may obtain commercial traction even without a novel excipient.

Clinical workflow risk

A new presentation must work within existing pharmacy protocols. Changes to diluent, concentration, storage temperature, infusion duration, or labeling can create medication-use barriers. Products that require special handling may lose against a familiar 500 mg or 1 g vial.

How strong is the patent estate for a new Merrem excipient product?

The patent estate is strong only if it protects a commercially meaningful product characteristic that competitors cannot easily reproduce through a different formulation or container.

Strategy	Patent potential	Commercial attractiveness	Development risk
Optimized sodium-carbonate powder	Moderate	Moderate	Low
Reduced-sodium powder	Moderate	Moderate	Moderate
Ready-to-use liquid bag	Moderate to strong	Strong	High
Dual-chamber system	Stronger device and formulation potential	Strong	High
Elastomeric pump	Moderate to strong	Niche to strong	High
New clinical indication	Potential method-of-use protection	Depends on indication	High
Conventional generic vial	Low incremental IP value	Price-driven	Low to moderate

A practical portfolio should combine composition claims, process claims, container claims, and stability claims. No single narrow formulation claim should carry the entire business case.

What licensing deals could support a meropenem commercial strategy?

Licensing opportunities are more likely to involve technology and manufacturing than the Merrem brand itself. Relevant counterparties include:

• Sterile injectable contract manufacturers.
• Dual-chamber and premix container developers.
• Elastomeric infusion-device companies.
• Hospital pharmacy automation suppliers.
• Regional generic distributors.
• Companies with approved meropenem ANDAs but limited manufacturing capacity.
• Developers with validated meropenem stability data in specialized containers.

A license should address territory, regulatory ownership, manufacturing responsibilities, shortage allocation, technology-transfer obligations, pharmacovigilance, recall costs, and rights to follow-on strengths or delivery systems.

How does Merrem compare with other carbapenem commercial opportunities?

Meropenem has a broad hospital use profile and is widely recognized by infectious-disease specialists. Its generic maturity reduces pricing power, but the large installed base supports differentiated delivery products.

Drug	Market position	Formulation opportunity	Key commercial issue
Meropenem	Broad-spectrum hospital carbapenem	Premix, dual chamber, extended infusion	Mature generic pricing
Ertapenem	Once-daily carbapenem	Ready-to-use and outpatient products	Lower dosing frequency reduces preparation demand
Imipenem/cilastatin	Established carbapenem combination	Stability and device systems	More complex active combination
Doripenem	Limited commercial relevance	Limited	Smaller market opportunity

Meropenem is more suitable than many older injectables for extended-infusion and outpatient delivery strategies because hospital protocols already use flexible infusion durations. The opportunity remains dependent on stability and payer or hospital willingness to pay.

What is the revenue exposure and commercial opportunity?

Revenue from a standard meropenem vial is exposed to generic price erosion, contract rebidding, and supplier substitution. A differentiated product can seek higher gross margin through labor savings and service value rather than through antibacterial differentiation.

The most credible commercial segments are:

1. Hospitals with high meropenem utilization.
2. Intensive care units using extended infusions.
3. Outpatient antimicrobial therapy programs.
4. Health systems facing sterile-compounding labor shortages.
5. Government and institutional purchasers seeking supply redundancy.
6. Pharmacy networks using automated dispensing and centralized compounding.

A conventional generic strategy may generate volume but limited margin. A premix, dual-chamber, or ambulatory infusion product has greater margin potential but requires substantially more investment, regulatory work, and manufacturing validation.

Key Takeaways

• Merrem IV is a simple sterile meropenem powder formulation using sodium carbonate as the principal excipient.
• The original Merrem compound and conventional formulation protections are no longer meaningful barriers to U.S. generic entry.
• The core commercial opportunity is delivery and workflow improvement, not a new antibacterial mechanism.
• Ready-to-use bags, dual-chamber systems, reduced-sodium formulations, and elastomeric devices are the most relevant development paths.
• Sodium carbonate remains the lowest-risk buffer platform because it is consistent with the established formulation.
• A new excipient system should be supported by composition, process, container, and stability patents.
• Sterile manufacturing reliability and hospital contracting are more important than Paragraph IV litigation for ordinary meropenem products.
• A conventional vial is a price-driven generic business; a differentiated delivery system can support higher value but carries greater regulatory and technical risk.

FAQs

Can sodium carbonate be replaced in a generic meropenem formulation?

Potentially, but the replacement would require evidence that the new buffer maintains meropenem stability, pH, impurity limits, osmolality, diluent compatibility, and intravenous usability.

Is meropenem suitable for a premixed infusion product?

Yes, but the principal development challenge is aqueous stability during labeled storage, transportation, temperature excursions, and administration.

Can a meropenem dual-chamber vial obtain new patent protection?

Yes. Patentable subject matter may include the chamber configuration, activation mechanism, formulation separation, reconstitution performance, and stability profile, subject to standard patentability requirements.

Does a new meropenem excipient require clinical trials?

Not necessarily. The requirement depends on the formulation difference, regulatory pathway, proposed labeling, and whether the applicant can establish equivalence and safety through pharmaceutical and nonclinical data. A materially novel product may require additional clinical support.

Is Merrem a strong target for biosimilar development?

No. Meropenem is a chemically synthesized small-molecule antibiotic, not a biologic. The relevant pathway is generic or 505(b)(2) development, not biosimilar approval under the Biologics Price Competition and Innovation Act.

References

1. U.S. Food and Drug Administration. (2019). Merrem I.V. (meropenem for injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for sterile products and injectable preparations. USP.